MCRB Jan 2026 2.500 call
| Previous Close | 0.6000 |
| Open | 0.6000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expire Date | 2026-01-16 |
| Day's Range | 0.6000 - 0.6000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 5 |
- Business Wire
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., May 08, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates.
- Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 06, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on May 1, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 9,367 shares of its common stock to two new employees, consisting of stock options to purchase 6,244 shares of common stock and restricted stock units ("RSUs") covering 3,123 shares of its common
- Business Wire
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
CAMBRIDGE, Mass., May 06, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates.
